Presenting Companies - LSI Asia '26

Lucas Decuypere

CEO, Allegro

Our lead product is Hydrocelin, a first-in-class, minimally invasive injectable therapy, designed as a disease-modifying treatment for osteoarthritis. Hydrocelin is designed to address the primary cause of osteoarthritis: the loss of the rheopectic and viscoelastic characteristics of the synovial fluid. Once injected, Hydrocelin mixes with the synovial fluid, where it adapts under load to absorb and dissipate impact forces and replicate the mechanics of healthy joint fluid through resilient nanostructured crosslinking. This restores joint function and relieves pain, while initiating a mechanobiological cascade that protects and potentially regenerates cartilage. Hydrocelin does not suppress symptoms. It corrects the physics of the joint and changes the trajectory of the disease.

Lloyd Mencinger

President & CEO, Aqua Medical

Aqua Medical’s through-the-endoscope, 30-minute outpatient treatment represents an intervention to enhance control for individuals with type 2 diabetes.

Arctx Medical, a clinical-stage medical technology company, is developing the world’s first targeted treatment for Acute Pancreatitis (AP). Local cooling is a well-established therapy for treating acute inflammatory conditions within the body. The Arctx Cool Catheter™ (ACC) Set delivers minimally invasive, localized, and potent cooling therapy to the pancreas, intended to reduce inflammation, accelerate patient recovery, and prevent more serious complications including organ failure and death. Arctx is embarking on an IDE-approved US pivotal clinical trial for this first-ever dedicated treatment for AP. The company has also received FDA marketing authorization for use of the ACC in patient temperature management, a second and mature market for its technology.

Enrique Vega

CEO, Azalea Vision

Azalea Vision is developing a solution for patients with conditions and disorders that increase sensitivity to light. The company's solution actively adapts and manages within a personalized contact lens. The lens will also be capable of compensating for refractive errors of the eye, such as astigmatism and myopia.

Jeremy Wheeler

CEO, BioCaptiva

BIOCAPTIVA develops msX™, a proprietary polymer-based platform that directly captures cell-free DNA and RNA from biological fluids, addressing the most critical bottleneck in liquid biopsy: pre-analytics. By enabling high-yield, low-contamination nucleic acid capture directly from whole blood and other biofluids, msX™ simplifies workflows, improves sensitivity, and is fully compatible with automation and OEM integration.

Ilan Uchitel

CEO, CAPS Medical

CAPS Medical is a medical device company focused on the development and commercialization of cancer treatment using Cold Atmospheric Plasma.

Shawn Zhuang

CEO, Cardiostory Inc

CardioStory is a clinical-stage medical technology company developing a Non-Invasive Filling Pressure (NIFP) measurement device for Heart Failure (HF) patients. The system utilizes proprietary fiber optic sensors and advanced algorithms to capture microscopic chest vibrations and accurately calculate pressure inside the heart in just two minutes. Differentiated by its ability to replace highly invasive catheters and surgical implants with a simple, non-invasive assessment, CardioStory aims to empower proactive heart failure management and significantly reduce costly hospital readmissions.

Jeremy Steele

CEO and Managing Director, Control Bionics

Control Bionics’ NeuroStrip and broader neurotechnology platform use surface electromyography (sEMG) to detect and interpret muscle activation signals, enabling real-time analysis of neuromuscular function. The platform integrates hardware and software to capture, process, and structure physiological data for applications in rehabilitation, assistive technology, and sports and human performance. It is already in use in the US, Europe, Australia and Japan.

Jochen Reinöhl

CEO, Coramaze Technologies

The TriPair™ Technology is a novel minimally invasive tricuspid repair solution designed to treat Tricuspid Regurgitation —a condition that affects millions globally, with the vast majority currently remaining untreated. TriPair™ simplifies transcatheter repair through an innovative edge-to-spacer approach, aiming to reduce procedural complexity and improve access to care. TriPair™ is designed to be simple, fast (procedure time under 30 minutes), and highly effective, empowering physicians in both established and underserved markets to treat patients who cannot be helped with existing technologies. Following a successful first-in-human trial, TriPair™ is now being prepared for evaluation in global feasibility studies across multiple continents.

Heeju Han

CEO, CoreMotion

CoreMotion is developing the PeriK System, a quantitative pelvic floor assessment and rehabilitation solution designed to measure pelvic floor function and enable data-driven, personalized therapy.

Erik Philip Nordenfelt

CEO, Cytely

Our mission is to make advanced imaging radically simpler and more insightful, so breakthroughs happen faster—and benefit everyone.

Kieran Mulroney

CEO, Cytophenix Pty Ltd

Cytophenix Pty Ltd is an early-stage medical diagnostics company developing FloCAST, an AI-powered platform for rapid Antimicrobial Susceptibility Testing (AST). The technology uses flow cytometry and machine learning to analyze how individual bacterial and fungal cells respond to antibiotics in real-time, delivering targeted treatment recommendations in three to four hours rather than days. Differentiated by its speed, single-cell resolution, and seamless laboratory integration, Cytophenix empowers doctors to treat sepsis more effectively, saving lives while combating global antibiotic resistance.

Indraneel Bardhan

Founder and Partner, EOS Intelligence

We deliver actionable business intelligence solutions by providing information and insights to help your business achieve success. To know more, connect today!

GuideAI Health automates the early detection of chronic vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts. The platform's first product addresses the 90% underdiagnosis/misdiagnosis rate of peripheral vascular disease in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.

Sujit Dike

CEO, Gyder Surgical

Gyder Surgical's Gyder Hip System is a non-invasive, pin-less navigation solution for total hip replacement. The system is an open platform that can be used with a surgeon's preferred implant system, reduces radiation exposure by not requiring CT or X-ray imaging, and seamlessly integrates into existing workflows due to the system's simple set-up and quick calibration.

Amy Mechley

Chief Clinical and Strategy Officer, HealthBook+

HealthBook+ is a clinical intelligence platform that surfaces actionable insights and guides people in their health. At the center of HealthBook+ is PaiGE, the Agentic Medical Partner, which analyzes medical records and lifestyle data to identify clinically relevant signals and support decision-making across care delivery, care navigation, and employer-sponsored health programs. The platform reduces time spent gathering and reviewing data, enabling clinicians to focus more on patient care.

Shirley Zhu

Head of Global Business Development, CEO of U.S. subsidiary, Hygea Medical Technology Co. Ltd

Hygea, as the No.1 Chinese Co-ablation developer had developed a strong pipeline in minimally Invasive Oncology area including 85℃/-196℃ Co-Ablation(FDA/CE/CFDA), Irreversible Electroporation(IRE), Microwave Ablation (MWA, FDA/CE/CFDA) systems and TACE Biodegradable Microspheres, based on its percutaneous ablation and Endovascular intervention platforms. More than 30K+ patients globally benefit from company’s innovation since its 1st Co-ablation system launched in 2017.

Peter Fischer

CEO, Inkspace Imaging

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics.

Michael Butler

Founder and Managing Partner, KinetiX Group | Board Member, Spinol Medical, Kinetix Group and Spinol

Spinol advances a new standard in annular repair.OctaSeal™ is a best-in-class, intradiscal annular closure technology—minimally invasive, tissue-preserving, and supported by five-year clinical data—addressing a ~$3B market with only one existing competitor. Visit website. https://spinolmed.com/

Maher Khaled

CEO, Luminoma Diagnostics

Luminoma is developing the LumAssure, a non-invasive point-and-click device that indicates whether a skin lesion is malignant or benign within seconds. The diagnostic-aid provides clinicians with assurance in their biopsy decision without having to wait days for a lab result. The LumAssure's high accuracy promises to avoid missing cancers and reduce unnecessary procedures and referrals, making clinics more efficient whilst improving patient outcomes.

Karmela Sliskovic

CEO, LyzeData (previously Freshvista)

LyzeData is a data intelligence platform focused on KPI definition and computation across heterogeneous data sources. It combines automated data ingestion, normalization, and validation to produce reliable, decision-ready metrics with minimal configuration.

Douglas Abrams

CFO, Meticuly

Meticuly is the only company with US FDA clearance for 3D-printed titanium patient-specific cranial mesh. Using AI-driven surgical planning software and precision additive manufacturing, Meticuly produces custom cranial implants that deliver superior anatomical fit and clinical outcomes compared to conventional alternatives.

Nico Fenu

Co-Founder and Chief Operating Officer, Nami Surgical

Nami Surgical has developed the world’s first miniaturized ultrasonic scalpel designed specifically for robotic-assisted surgery and the only ultrasonic technology engineered to articulate through wristed robotic joints. This represents a major unmet need in robotic surgery, where ultrasonic energy solutions remain constrained by size, articulation, and integration limitations.

Sander Bangma

CEO, Navier Medical Ltd

Navier Medical offers Mosaic, an FDA-cleared, AI-driven software platform for the advanced evaluation of cardiovascular disease from standard CT angiography scans. The technology provides comprehensive 3D visualization and quantifies high-risk arterial plaque burden, allowing clinicians to detect hidden disease often missed by routine assessments. Differentiated by its ability to uncover deep, patient-specific cardiovascular risks without altering the standard imaging workflow, Navier Medical aims to prevent severe cardiac events through earlier, more personalized intervention.

Alur Saguinsin

Founder & CEO, One kidney

OneKidney is developing a renal replacement platform based on a proprietary membrane architecture. The technology is being advanced through a staged development pathway, beginning with extracorporeal and wearable applications and progressing toward a fully implantable artificial kidney, with the core membrane engineered to increase effective surface area and enable continuous solute transport across all phases.

Marcin Golebicki

CEO and Founder, ReNavie Sensing

ReNavie Sensing is the new novel technology focusing on mapping Renal Denervation and solving non responder issue.

Trang Nguyen

CEO, SeeTreat Medical

SeeTreat Medical is a software company developing ART.1, an automated decision-support platform for adaptive radiotherapy. The Software as a Medical Device (SaMD) continuously analyzes daily volumetric imaging to track anatomical changes and calculate delivered radiation doses, instantly alerting clinical teams if a patient's treatment plan needs adjustment. Differentiated by its ability to integrate seamlessly with existing linear accelerators without requiring hardware upgrades, SeeTreat enables oncology clinics to efficiently provide personalized, precision cancer treatments.

Justin Anderson

Chief Executive Officer, President, and Chairman, Tensor Surgical

Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company’s portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures.

John Santini

President & CEO, Vergent Bioscience

Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

Sam Yang

CEO / Co-founder, Xandar Kardian

Pioneers of radar based, ambient health monitoring. Their XK300 sensor is FDA cleared in 6 countries, including the U.S. where they collected 2,750 years' worth of data from 44,000 unique patients to date. Equipped with unique biometric data from patterns of vibrations (breathing/heart), the company was able to create AI models that accurately predicted UTI, Heart Failure, COVID, COPD and even death at 74%~89% accuracy, 4-6 days prior to an event.

Want to present at LSI Asia ‘26?

Want to present at
LSI Asia ‘26?